(Q34807486)

4 August 2017

1 reference

title

Antifungal drug resistance to azoles and polyenes (English)

1 reference

antifungal drug resistance

4 August 2017

main subject

1 reference

Mar Masiá Canuto

1

1 reference

4 August 2017

Félix Gutiérrez Rodero

series ordinal

2

1 reference

4 August 2017

publication date

1 September 2002

1 reference

Lancet Infectious Diseases

4 August 2017

published in

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

550-563

1 reference

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Aspergillosis case-fatality rate: systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Oral azole drugs as systemic antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Prophylactic oral fluconazole and candida fungaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

An analysis of the trends in the use of antifungal drugs and fungal isolates in a UK University Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

An audit of the use of antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Present status of the detection of antifungal resistance: the perspective from both sides of the ocean

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The epidemiology of hematogenous candidiasis caused by different Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathog

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Candida glabrata Fungemia. Clinical features of 139 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Importance of Candida species other than C. albicans as pathogens in oncology patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Candida krusei fungemia. An escalating serious infection in immunocompromised patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Amphotericin B: spectrum and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Amphotericin B-resistant yeast infection in severely immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Disseminated Candidiasis Due to Amphotericin B-Resistant Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Cross-resistance to polyene and azole drugs in Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The effects of the polyene antibiotics nystatin and amphotericin B on thin lipid membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Molecular mechanisms of drug resistance in fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Polyene-resistant mutants of Aspergillus fennelliae: identification of sterols

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Incidence of polyene-resistant yeasts recovered from clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Polyene resistance and the isolation of sterol mutants in Saccharomyces cerevisiae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Antimicrobial-drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Determinants for the Development of Oropharyngeal Colonization or Infection by Fluconazole-Resistant Candida Strains in HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Candidemia in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Eight-year surveillance of non-albicans Candida spp. in an oncology department prior to and after fluconazole had been introduced into antifungal prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Clinical features of human infection with Scedosporium inflatum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The crisis in antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Antibiotics that inhibit fungal cell wall development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Treatment of murine Candida krusei or Candida glabrata infection with L-743,872

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Treatment of histoplasmosis with MK-991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Azole Antifungal Agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Voriconazole: a new triazole antifungal

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Zygomycosis in relapsed acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Unusual etiology of visual loss in an HIV-infected patient due to endogenous endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Caspofungin acetate: an antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Combination therapy with caspofungin and amphotericin B lipid complex.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The exciting future of antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Adjunctive immune therapy for fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Does immune serum globulin confer protection against skin diseases?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Fungemia in patients with hematologic malignancies: therapeutic effects of concomitant administration of fluconazole and granulocyte-colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Successful treatment of invasive thoracopulmonary mucormycosis in a patient with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: response to GM-CSF therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Adjuvant therapy with rhGM-CSF for the treatment of Blastoschizomyces capitatus systemic infection in a patient with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony-stimulating factor (GM-CSF).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Immunorestitution disease involving the innate and adaptive response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Interferon-gamma in the management of chronic granulomatous disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Aspergillus fumigatus conidia induce a Th1-type cytokine response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Interleukin 12 as an adjuvant to WI-1 adhesin immunization augments delayed-type hypersensitivity, shifts the subclass distribution of immunoglobulin G antibodies, and enhances protective immunity to Blastomyces dermatitidis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Interleukin-12 regulation of host defenses against Coccidioides immitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900371-7

7 January 2021

10.1016/S1473-3099(02)00371-7

Identifiers

DOI

1 reference

4 August 2017

1 reference